Routine conference participation filing with no material new information. The Jefferies presentation may provide incremental color on Zelsuvmi prescription trends and pipeline timelines, but this filing alone does not warrant a position change. Monitor for any material updates during the conference on June 4.
Price Chart
Executive Summary
Pelthos Therapeutics filed an 8-K announcing that CEO Scott Plesha will present and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The filing includes a corporate presentation (Ex-99.2) highlighting Zelsuvmi launch progress (>20,000 units dispensed through April 2026, QoQ TRx growth), the Xepi and Xeglyze acquisitions, and a $32M cash position. No new financial guidance or material business developments were disclosed.
Key Facts
- CEO Scott Plesha to present at Jefferies Global Healthcare Conference on June 4, 2026
- Zelsuvmi units dispensed: >20,000 from July 2025 launch through April 2026
- Zelsuvmi TRx grew from 2,578 (Q3 2025) to 7,884 (Q1 2026); prescribers grew from 1,223 to 3,228
- Cash at end of Q1 2026: $32.0M
- Stock price: $26.85; market cap ~$240M; ~8.9M shares outstanding (with preferred A conversion)
- Xepi (impetigo) relaunch expected early 2027; Xeglyze (head lice) launch expected mid-2027
- 64 sales territories covering ~53% of MC claims
Financial Impact
No new financial data or guidance provided; filing is a routine conference participation announcement with an updated corporate presentation
Risk Factors
- No new financial guidance or operational updates beyond previously disclosed metrics
- Forward-looking statements in the presentation are aspirational and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001919246-26-000085 |
| Exhibit: exhibit992.htm | 0001919246-26-000085 |
| Document: pths-pressreleasex20260528.htm | 0001919246-26-000085 |
| Document: 0001919246-26-000085-index-headers.html | 0001919246-26-000085 |
| Document: 0001919246-26-000085-index.html | 0001919246-26-000085 |
| Document: 0001919246-26-000085.txt | 0001919246-26-000085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers